Nextage Therapeutics Ltd
Tel Aviv Stock Exchange NXTG.TA
Nextage Therapeutics Ltd EBITDA for the year ending December 31, 2023: USD -1.11 M
Nextage Therapeutics Ltd EBITDA is USD -1.11 M for the year ending December 31, 2023, a 33.92% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
-
Nextage Therapeutics Ltd EBITDA for the year ending December 31, 2022 was USD -1.68 M, a 31.27% change year over year.
-
Nextage Therapeutics Ltd EBITDA for the year ending December 31, 2021 was USD -2.44 M, a 50.55% change year over year.
-
Nextage Therapeutics Ltd EBITDA for the year ending December 31, 2020 was USD -4.94 M, a -288.11% change year over year.
-
Nextage Therapeutics Ltd EBITDA for the year ending December 31, 2019 was USD -1.27 M, a -10.21% change year over year.
Key data
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: NXTG.TA
| CEO | Mr. Abraham Dreazen |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | Einstein St. Building 13B |
| Employees | 42 |
| Sector | Health Care |
| Industries | |
Description
Nextage Therapeutics Ltd develops cannabinoid-based products. The company is based in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email